Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCX7353 DDI Study with CYP Probes
NCT02819102Phase 1Completed
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Mar 2016
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of berotralstat in hereditary angioedema (HAE), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoints: Maximum Plasma Concentration (Cmax) of Probe Substrates at Day 11, Time to Maximum Plasma Concentration (Tmax) of Probe Substrates at Day 11 and 4 more. Started Mar 2016; status: completed.
02
Drugs
berotralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT02819102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02819102.